FDA alerts providers to recall of drug to treat serious bacterial infections
The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.
Related News Articles
Headline
Hartford HealthCare in Hartford, Conn., will receive the 2025 AHA Quest for Quality Prize as a result of their sweeping transformation over the past decade —…
Headline
A Q&A in the July edition of AHA Trustee Insights features leaders from Winchester Hospital in Massachusetts discussing the importance of board members…
Headline
To help hospitals across the country improve sepsis care, the Centers for Disease Control and Prevention created the Hospital Sepsis Program Core Elements,…
Headline
The Centers for Disease Control and Prevention July 7 announced it is streamlining H5N1 bird flu updates with its routine influenza data given the low public…
Headline
The United States July 7 reached its highest annual measles case tally in 33 years, hitting at least 1,277 confirmed cases across 38 states and the District of…
Headline
AHA President and CEO Rick Pollack explains how hospitals have made meaningful progress in patient safety and delivering high-quality care, in a column…